Singen, November 5, 2019. The Japanese pharmaceutical company Takeda has opened the first dengue vaccine factory in Germany. The company invested 130 million euros in the location Singen. Takeda is currently expecting approval by next year. The vaccine is still in approval-relevant phase 3 of the TIDES study (Tetravalent Immunization against Dengue Efficacy Study) and is being carried out in the dengue-endemic countries of Latin America and Asia. Dr. Dr. Carsten Köhler, member of the board of the DNTDs and director of the Competence Center Tropical Medicine Baden-Württemberg, Institute for Tropical Medicine of the University Clinic of the Eberhard-Karls-University Tübingen, points out that dengue is no longer just a travel illness and illness of neglected people, but already occurs locally in Europe.
